scholarly journals Antibodies Against SARS-CoV-2 in Human Milk: Milk Conversion Rates in the Netherlands

2021 ◽  
pp. 089033442110181
Author(s):  
Hannah G. Juncker ◽  
Michelle Romijn ◽  
Veerle N. Loth ◽  
Eliza J. M. Ruhé ◽  
Sjors Bakker ◽  
...  
Keyword(s):  
The Netherlands ◽  
Human Milk ◽  
Immunoglobulin A ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Breastfed Infants ◽  
Lactating Mothers ◽  
Conversion Rates ◽  
Iga Antibodies ◽  
Large Prospective Cohort Study

Background It has been demonstrated that human milk from mothers who have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains antibodies against the virus, which could play an important role in protecting the recipient infant against coronavirus disease 2019 (COVID-19). Seroconversion is measured frequently around the world, but the milk conversion rate is unknown. Research Aims To determine (1) the prevalence and (2) the dynamics of immunoglobulin A (IgA) antibodies against SARS-CoV-2 in human milk amongst lactating mothers in the Netherlands. Methods In this large prospective cohort study, lactating mothers ( N = 2312) were included between October 12, 2020 and February 24, 2021. Enzyme-linked immunosorbent assay was used to determine levels of IgA antibodies in human milk and immunoglobulin G (IgG) antibodies in serum against the ectodomain of the SARS-CoV-2 spike protein. Results A total of 691 (30.6%) participants had SARS-CoV-2 specific antibodies in human milk and/or serum. Of these participants, 524 (23.1%) had IgA antibodies against SARS-CoV-2 in human milk, and 356 (15.7%) had IgG antibodies against SARS-CoV-2 in serum. A total of 199 (8.8%) participants had antibodies in both human milk and serum. SARS-CoV-2 specific IgA antibodies in human milk remain present at least 10 months after a polymerase chain reaction confirmed infection. Conclusion The prevalence of IgA antibodies against SARS-CoV-2 in human milk was 23.1% in our cohort. This high prevalence of antibodies in human milk might lead to passive immunity in many breastfed infants and may serve as protection against COVID-19.

scholarly journals Human Milk Antibodies Against SARS-CoV-2: A Longitudinal Follow-Up Study

2021 ◽  
pp. 089033442110301
Author(s):  
Hannah G. Juncker ◽  
M. Romijn ◽  
Veerle N. Loth ◽  
Tom G. Caniels ◽  
Christianne J.M. de Groot ◽  
...  
Keyword(s):  
Human Milk ◽  
Clinical Symptoms ◽  
Immunoglobulin A ◽  
Spike Protein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Follow Up Study ◽  
Lactating Mothers ◽  
Milk Antibodies ◽  
Over Time

Background: Human milk contains antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) following Coronavirus Disease 2019 (COVID-19). These antibodies may serve as protection against COVID-19 in infants. However, the evolution of these human milk antibodies over time is unclear. Research Aim: To elucidate the evolution of immunoglobulin A (IgA) against SARS-CoV-2 in human milk after a SARS-CoV-2 infection. Methods: This longitudinal follow-up study included lactating mothers ( N = 24) who had participated in the COVID MILK study. To assess the evolution of SARS-CoV-2 antibodies, serum and human milk samples were collected 14–143 days after the onset of clinical symptoms related to COVID-19. Enzyme-Linked ImmunoSorbent Assay was used to detect antibodies against the ectodomain of the SARS-CoV-2 spike protein. Results: SARS-CoV-2 antibodies remain present up to 5 months (143 days) in human milk after onset of COVID-19 symptoms. Overall, SARS-CoV-2 IgA in human milk seems to gradually decrease over time. Conclusion: Human milk from SARS-CoV-2 convalescent lactating mothers contains specific IgA antibodies against SARS-CoV-2 spike protein up to at least 5 months post-infection. Passive viral immunity can be transferred via human milk and may serve as protection for infants against COVID-19. Dutch Trial Register on May 1st, 2020, number: NL 8575, URL: https://www.trialregister.nl/trial/8575 .

scholarly journals Optimization of a human milk–directed quantitative sIgA ELISA method substantiated by mass spectrometry

2021 ◽  
Author(s):  
Kelly A. Dingess ◽  
Pauline van Dam ◽  
Jing Zhu ◽  
Marko Mank ◽  
Karen Knipping ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Human Milk ◽  
Immunoglobulin A ◽  
Secretory Component ◽  
Detection Methods ◽  
Enzyme Linked Immunosorbent Assay ◽  
Breastfed Infants ◽  
Serum Iga ◽  
Standard Serum ◽  
Analytical Approaches

AbstractImmunoglobulins are the primary protective products in human milk and are responsible for transferring maternal pathogen memory to the infant, providing protection by binding to recognized pathogens and inhibiting virulence. To better understand potentially protective/anti-infective compounds in human milk, the establishment of human milk–tailored analytical approaches is crucial, as most contemporary analytical methods have been optimized for plasma or serum. One of the most prominent immunoglobulins in human milk is secretory immunoglobulin A (sIgA), which may be relevant for the protection of breastfed infants from harmful pathogens. Advanced sIgA detection methods can help monitor the immune status and development of the mother-infant dyad. We therefore developed an enzyme-linked immunosorbent assay (ELISA) sIgA method for the quantitative analysis of IgA plus secretory component (SC), validated with sIgA standards and substantiated by mass spectrometry (MS)–based proteomics. A very strong correlation was observed between the MS-detected IgA1 and the human milk–specific sIgA ELISA (r = 0.82). Overall, the MS data indicate that the developed human milk sIgA ELISA does not differentiate between sIgA1 and sIgA2 and is, therefore, a reflection of total sIgA. Furthermore, our MS data and the human milk–derived sIgA ELISA data are better correlated than data derived from a standard serum IgA ELISA kit (relative to MS IgA1 r = 0.82 and r = 0.42, respectively). We therefore propose our human milk–specific sIgA ELISA as an ideal quantitative indicator of total sIgA with advantages over current serum IgA ELISA kits.

scholarly journals Identification of the Entamoeba histolytica Galactose-Inhibitable Lectin Epitopes Recognized by Human Immunoglobulin A Antibodies following Cure of Amebic Liver Abscess

2004 ◽  
Vol 72 (7) ◽  
pp. 3974-3980 ◽  
Author(s):  
Mohamed D. Abd-Alla ◽  
Terry F. G. H. Jackson ◽  
Ginny C. Soong ◽  
Mary Mazanec ◽  
Jonathan I. Ravdin
Keyword(s):  
Entamoeba Histolytica ◽  
Liver Abscess ◽  
Clinical Status ◽  
Immunoglobulin A ◽  
Enzyme Linked Immunosorbent Assay ◽  
Amebic Liver Abscess ◽  
Igg Antibodies ◽  
Intestinal Infection ◽  
Iga Antibodies ◽  
Intestinal Iga

ABSTRACT Immunity to Entamoeba species intestinal infection is associated with the presence of intestinal IgA antibodies against the parasite's galactose-inhibitable adherence lectin. We determined the epitope specificity of serum and intestinal antilectin IgA antibodies by enzyme-linked immunosorbent assay using overlapping fragments of a recombinant portion of the lectin heavy subunit, designated LC3. These findings were correlated with the effects of epitope-specific murine antilectin immunoglobulin A (IgA) monoclonal antibodies (MAbs) on amebic in vitro galactose-specific adherence. LC3 is a highly antigenic and immunogenic cysteine-rich protein (amino acids [aa] 758 to 1150) that includes the lectin's carbohydrate binding domain. The study subjects, from Durban, South Africa, were recently cured of amebic liver abscess (ALA) with or without concurrent Entamoeba histolytica intestinal infection or were infection free 1 year after cure. We also studied seropositive subjects that were infected with E. histolytica, disease free, and asymptomatic. Serum anti-LC3 IgA antibodies from all study groups exclusively recognized the third (aa 868 to 944) and the seventh (aa 1114 to 1134) LC3 epitopes regardless of clinical status; epitope 6 (aa 1070 to 1114) was also recognized by serum anti-LC3 IgG antibodies. However, IgG antibody recognition of epitope 6 but not 3 or 7 was lost 1 year following cure of ALA. We produced 14 murine anti-LC3 IgA MAbs which collectively recognized five of the seven LC3 epitopes. The majority of the murine MAbs recognized the first epitope (aa 758 to 826), which was not recognized by human IgA antibodies. Interestingly, adherence of E. histolytica trophozoites to CHO cells was inhibited by MAbs against epitopes 1, 3, 4 (aa 944 to 987), and 6 (P < 0.01). The LC3 epitopes recognized by human IgA antibodies (3 and 7) were further characterized by use of overlapping synthetic peptides. We identified four peptides (aa 891 to 903, 918 to 936, 1114 to 1134, and 1128 to 1150) that in linear or cyclized form were recognized by pooled intestinal IgA antibodies and serum IgG antibodies from subjects with ALA and asymptomatic, seropositive infected subjects. This study identifies the lectin epitopes to be studied in an amebiasis subunit vaccine designed to elicit mucosal immunity mimicking that of humans cured of ALA.

scholarly journals Fecal Immunoglobulin A Antibodies in Dogs Infected or Vaccinated with Canine Coronavirus

2004 ◽  
Vol 11 (1) ◽  
pp. 102-105 ◽  
Author(s):  
Nicola Decaro ◽  
Annamaria Pratelli ◽  
Antonella Tinelli ◽  
Vito Martella ◽  
Michele Camero ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Immunoglobulin A ◽  
Enzyme Linked Immunosorbent Assay ◽  
Inactivated Vaccine ◽  
Secretory Immunoglobulin A ◽  
Intramuscular Route ◽  
Degree Of Protection ◽  
Canine Coronavirus ◽  
Iga Antibodies ◽  
Secretory Immunoglobulin

ABSTRACT Fecal secretory immunoglobulin A (IgA) antibodies in dogs infected or vaccinated with canine coronavirus (CCV) were evaluated by an enzyme-linked immunosorbent assay. The study was carried out with 32 fecal samples collected just before inoculation and at 28 days postinoculation. Five groups were studied: naturally infected dogs, experimentally infected dogs, dogs inoculated with a modified live (ML) CCV vaccine by the intramuscular route, dogs inoculated with an ML CCV vaccine by the oronasal route, and dogs given an inactivated CCV vaccine. Both the naturally and the experimentally infected dogs developed high levels of fecal IgAs. Interestingly, dogs inoculated with the ML CCV vaccine by the oronasal route developed levels of fecal IgA that were higher than those observed in the dogs inoculated with the same CCV vaccine by the intramuscular route or those observed in dogs inoculated with the inactivated vaccine. A relationship between the level of fecal IgAs to CCV and the degree of protection against CCV infection was observed.

scholarly journals Immunoglobulins G, M, and A against Sporothrix schenckii Exoantigens in Patients with Sporotrichosis before and during Treatment with Itraconazole

2007 ◽  
Vol 14 (9) ◽  
pp. 1149-1157 ◽  
Author(s):  
Rodrigo Almeida-Paes ◽  
Monique Amorim Pimenta ◽  
Paulo Cezar F. Monteiro ◽  
Joshua D. Nosanchuk ◽  
Rosely Maria Zancopé-Oliveira
Keyword(s):  
Sporothrix Schenckii ◽  
Cross Reactivity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Number Of Patients ◽  
Highly Sensitive ◽  
Iga Antibodies ◽  
Itraconazole Treatment ◽  
Few Data ◽  
Humoral Responses

ABSTRACT Sporotrichosis is an important subcutaneous mycosis, with an increasing worldwide incidence. However, few data are available regarding the immunological aspects of Sporothrix schenckii infection, particularly the humoral responses to the fungus. In this study we measured immunoglobulin G (IgG), IgM, and IgA in sera from 41 patients with sporotrichosis before antifungal treatment and from another 35 patients with sporotrichosis during itraconazole treatment by using a recently described S. schenckii exoantigen enzyme-linked immunosorbent assay (ELISA). More than 95% of patients had detectable IgA antibodies, and more than 85% had IgM and IgG antibodies before treatment. The number of patients with IgG antibodies increased to 91% during treatment. Conversely, significantly fewer samples from treated patients were positive for IgM (71%) and IgA (89%). Overall, 78% of patients had detectable levels of all isotypes tested at diagnosis, and this percentage dropped to 62.9% in patients receiving itraconazole. Testing of all three isotypes improved the sensitivity; at least two isotypes were detected in 93% of patients before and 89% after treatment. The reactivity of 94 sera from patients with other diseases and healthy individuals was also tested. Cross-reactivity occurred in 33% of the heterologous sera. Most of them were positive only in one isotype, 8.5% were positive for at least two isotypes, and only one serum (1.1%) was positive for the three isotypes. Antibodies produced during S. schenckii infection are diverse, and we demonstrate that an exoantigen ELISA for the detection of combinations of IgA, IgG, and IgM antibodies is a highly sensitive and specific diagnostic assay for sporotrichosis.

Salivary IgA and serum IgA and IgG antibodies to Candida albicans in HIV-infected subjects

2002 ◽  
Vol 13 (6) ◽  
pp. 373-377 ◽  
Author(s):  
M Belazi ◽  
A Fleva ◽  
D Drakoulakos ◽  
D Panayiotidou
Keyword(s):  
Immune Response ◽  
Candida Albicans ◽  
Study Groups ◽  
Secretory Iga ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Igg Antibodies ◽  
Serum Iga ◽  
Whole Saliva ◽  
Iga Antibodies

This study sought to determine IgA, IgG antibodies to Candida albicans in whole saliva and serum from HIV-infected patients and to compare them to a group of healthy controls. The study population consisted of 34 HIV-infected individuals free of any other systemic diseases and thirty healthy controls. IgA concentrations in saliva and IgA and IgG concentrations in serum were measured by a micro enzyme-linked immunosorbent assay. No significant differences were observed in salivary and serum IgA antibodies to C. albicans between the two study groups. Serum IgG antibodies were found to be significantly lower in the HIV-infected ( P < 0.05). No significant changes were observed in the specific activity of anti-Candida IgA and IgG antibodies in saliva and serum, in both the study groups. The undifferentiated levels of secretory-IgA antibodies to C. albicans in the patients' and the controls' saliva could be an indicator of the high immune response to opportunistic infections of the HIV-infected subjects, a fact that is verified by the lack of oral candidiasis in the patients' group. The low levels of IgG antibodies in the serum of the HIV-infected patients confirm the high immune response of them.

scholarly journals Survival of vaccine-induced human milk SARS-CoV-2 IgG and IgA immunoglobulins across simulated human infant gastrointestinal digestion

2021 ◽  
Author(s):  
Myrtani Pieri ◽  
Vicky Nicolaidou ◽  
Irene Paphiti ◽  
Spyros Pipis ◽  
Kyriacos Felekkis ◽  
...  
Keyword(s):  
Human Milk ◽  
Enzymatic Degradation ◽  
Natural Infection ◽  
In Vitro Digestion ◽  
Human Infant ◽  
European Medicines Agency ◽  
Igg Antibodies ◽  
Gi Tract ◽  
Lactating Mothers

Four vaccines have been approved to date by the European Medicines Agency for the management of the COVID-19 pandemic in Europe, with all four being targeted to adults over 18 years of age. One way to protect the younger population such as infants or younger children until pediatric vaccines are licensed is through passive immunity via breastfeeding. Recent evidence points to the fact that human milk contains immunoglobulins (Ig) against the SARS-CoV-2 virus, both after natural infection or vaccination, but it is not known whether these antibodies can resist enzymatic degradation during digestion in the infant gastrointestinal (GI) tract or indeed protect the consumers. Here, we describe our preliminary experiments where we validated commercially available ELISA kits to detect IgA and IgG antibodies in human milk from two lactating mothers vaccinated with either the Pfizer/BioNTech or the Astra Zeneca vaccine, and the effect of a static in vitro digestion protocol on the IgA and IgG concentrations. Our data, even preliminary, provide an indication that the IgA antibodies produced after vaccination with the Pfizer/BioNTech vaccine resist the gastric phase but are degraded during the intestinal phase of infant digestion, whereas the IgGs are more prone to degradation in both phases of digestion. We are in the process of recruiting more individuals to further evaluate the vaccine-induced immunoglobulin profile of breastmilk, and the extent to which these antibodies can resist digestion in the infant GI tract.

scholarly journals Modified Immunogenicity of a Mucosally Administered Antigen

2001 ◽  
Vol 8 (3) ◽  
pp. 540-544 ◽  
Author(s):  
Richard L. Gregory
Keyword(s):  
Immune System ◽  
Immunoglobulin A ◽  
Human Saliva ◽  
Mucosal Immune System ◽  
Antigenic Determinants ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Naturally Occurring ◽  
The Common

ABSTRACT Streptococcus mutans is present in the saliva of most individuals and is modified by salivary components bound to the cells. These saliva-bound S. mutans are swallowed, exposed to high levels of acidity in the stomach, and presented to the common mucosal immune system. Much effort has been directed to identifying the specific S. mutans antigens that the mucosal immune responses are directed against. However, little is known about the host-altered antigenic determinants that the mucosal immune system recognizes. The immunogenicity of gastrically intubated untreatedS. mutans cells, cells coated with whole human saliva, cells treated with HCl (pH 2.0), and saliva-coated and acid-treated cells in mice was investigated. Saliva and serum samples were assayed by enzyme linked immunosorbent assay for immunoglobulin A (IgA) and IgG antibodies, respectively, against the untreated or treated S. mutans cells. In general, the levels of salivary IgA and serum IgG antibodies to the antigen against which the mice were immunized were significantly higher (P ≤ 0.05). In addition, human saliva and serum samples from 12 subjects were assayed for naturally occurring antibody against the untreated or treated S. mutans cells. In every case, significantly higher reactivity was directed against the saliva-coated and acid-treated cells followed by the saliva-coated S. mutans. These results provide evidence for the altered immunogenicity of swallowed S. mutans in humans by coating native S. mutans antigens with salivary components and/or denaturing surface S. mutans antigens in the acidic environment of the stomach, which would lead to an immune response to modified S. mutans determinants and not to native S. mutans antigens.

scholarly journals Immunoglobulin G and A Antibody Responses to Bacteroides forsythus and Prevotella intermedia in Sera and Synovial Fluids of Arthritis Patients

2003 ◽  
Vol 10 (6) ◽  
pp. 1043-1050 ◽  
Author(s):  
Ketil Moen ◽  
Johan G. Brun ◽  
Tor Magne Madland ◽  
Turid Tynning ◽  
Roland Jonsson
Keyword(s):  
Immune Responses ◽  
Immunoglobulin G ◽  
Enzyme Linked Immunosorbent Assay ◽  
Prevotella Intermedia ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Igg Antibody ◽  
Iga Antibodies ◽  
Iga Antibody ◽  
Antibody Levels

ABSTRACT The objective of the present study was to investigate immunoglobulin G (IgG) and IgA antibody immune responses to Porphyromonas gingivalis, Prevotella intermedia, Bacteroides forsythus, and Candida albicans in the sera of patients with rheumatoid arthritis (RA), the synovial fluid (SF) of patients with RA (RA-SF samples), and the SF of patients without RA (non-RA-SF samples). An enzyme-linked immunosorbent assay was used to determine IgG and IgA antibody levels in 116 serum samples from patients with RA, 52 RA-SF samples, and 43 non-RA-SF samples; and these were compared with those in SF samples from 9 patients with osteoarthritis (OA-SF samples) and the blood from 100 donors (the control [CTR] group). Higher levels of IgG antibodies against B. forsythus (P < 0.0001) and P. intermedia (P < 0.0001) were found in non-RA-SF samples than in OA-SF samples, and higher levels of IgG antibodies against B. forsythus (P = 0.003) and P. intermedia (P = 0.024) were found in RA-SF samples than in OA-SF samples. Significantly higher levels of IgA antibodies against B. forsythus were demonstrated in both RA-SF and non-RA-SF samples than in OA-SF samples. When corrected for total Ig levels, levels of IgG antibody against B. forsythus were elevated in RA-SF and non-RA-SF samples compared to those in OA-SF samples. Lower levels of Ig antibodies against B. forsythus were found in the sera of patients with RA than in the plasma of the CTR group for both IgG (P = 0.003) and IgA (P < 0.0001). When corrected for total Ig levels, the levels of IgG and IgA antibodies against B. forsythus were still found to be lower in the sera from patients with RA than in the plasma of the CTR group (P < 0.0001). The levels of antibodies against P. gingivalis and C. albicans in the sera and SF of RA and non-RA patients were comparable to those found in the respective controls. The levels of IgG and IgA antibodies against B. forsythus were elevated in SF from patients with RA and non-RA-SF samples compared to those in OA-SF samples. Significantly lower levels of IgG and IgA antibodies against B. forsythus were found in the sera of patients with RA than in the plasma of the CTR group. This indicates the presence of an active antibody response in synovial tissue and illustrates a potential connection between periodontal and joint diseases.

Role of Maternal Allergy on Immune Markers in Colostrum and Secretory Immunoglobulin A in Stools of Breastfed Infants

2015 ◽  
Vol 32 (1) ◽  
pp. 160-167 ◽  
Author(s):  
Man-Chin Hua ◽  
Chien-Chang Chen ◽  
Tsung-Chieh Yao ◽  
Ming-Han Tsai ◽  
Sui-Ling Liao ◽  
...  
Keyword(s):  
Immunoglobulin E ◽  
Allergic Sensitization ◽  
Immunoglobulin A ◽  
Birth Cohort Study ◽  
Allergy Prevention ◽  
Secretory Immunoglobulin A ◽  
Immune Markers ◽  
Breastfed Infants ◽  
Lactating Mothers ◽  
Secretory Immunoglobulin

Background: Although protection against infectious diseases has been observed among breastfed infants as compared to formula-fed infants, possible benefits of breastfeeding by allergic mothers for allergy prevention remain controversial. Objectives: The aims of this study were to determine whether maternal allergy would influence immune markers (secretory immunoglobulin A [sIgA], interleukin-8 [IL-8], soluble CD14 [sCD14]) in colostrum and the associations between maternal allergy and fecal sIgA levels in breastfed infants. Methods: Study subjects were enrolled from the Prediction of Allergies in Taiwanese Children (PATCH) birth cohort study. Colostrum samples were obtained from 98 lactating mothers. Stool samples were collected from 108 infants within 5 days after birth and at 2 and 4 months of age. We compared concentrations of sIgA, IL-8, and sCD14 in colostrum between mothers with and without a history of allergic disease and allergic sensitization. We also compared fecal sIgA levels between breastfed and formula-fed infants and between infants with allergic and nonallergic mothers. Results: The sIgA concentrations were significantly higher in colostrum from allergic mothers than from nonallergic mothers ( P = .01) and from allergic mothers who were immunoglobulin E (IgE) sensitized compared to nonallergic mothers who were not IgE sensitized ( P = .023). Breastfed infants had significantly higher fecal sIgA levels as compared to formula-fed infants, regardless of whether their lactating mothers had an allergy ( P < .05). Conclusion: We found that breastfeeding is associated with increased infants’ fecal sIgA levels and may have potential protective effects to the infants during the first 4 months of life, regardless of whether their lactating mothers have allergies.

Sign in / Sign up

Export Citation Format

Share Document